Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DietPro is an herbal dietary supplement containing ephedra alkaloids, primarily ephedrine and pseudoephedrine, derived from the plant *Ephedra sinica* (Ma Huang). Historically marketed for weight loss and energy enhancement, it functions as a sympathomimetic agent by stimulating alpha- and beta-adrenergic receptors. This stimulation increases metabolic rate (thermogenesis) and suppresses appetite. The Johns Hopkins Bloomberg School of Public Health conducted clinical research (NCT00028067) to evaluate the safety and efficacy of DietPro on metabolism, hunger, and cardiovascular parameters in obese individuals. However, due to significant safety concerns including increased risks of hypertension, myocardial infarction, and stroke, the U.S. FDA banned the sale of dietary supplements containing ephedra alkaloids in 2004.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DietPro.